Results 161 to 170 of about 5,563 (240)

Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody

11451153Chimeric antigen receptor (CAR) T cells and bispecific T cell engagers have become integral components in the treatment of relapsed/refractory multiple myeloma.
Merz, Maximilian, Große, Florian, Fandrei, David, Meinel, Jörn, Pham, Nhu-Nguyen, Platzbecker, Uwe, Klepzig, Hanna, Pflug, Natali, Hallek, Michael, Herling, Marco, Kuschel, Florian, Richardson, Tim, Kreuz, Markus, Rade, Michael, Schweinsberg, Viola, Reiche, Kristin, Köhl, Ulrike, Löffler, Dennis, Braun, Till, Kuhn, Christina Katharina, Scheid, Christof, Holtick, Udo, Heger, Eva   +22 more
core   +1 more source

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

European Journal of Haematology, Volume 117, Issue 1, Page 24-41, July 2026.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Marco Fiorillo, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy. [PDF]

JACC CardioOncol
Itzhaki Ben Zadok O, Shimony S, Miller S, Stein D, Hossain S, Bianchi G, Nohria A.   +6 more
europepmc   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, Volume 117, Issue 1, Page 144-153, July 2026.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

Navigating the Future of Respiratory Infections: Key Insights From International Congress in Singapore, 17–20 September 2025

Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Background The 8th International Society for Respiratory Viruses (ISRV) Antiviral Group Conference, held jointly with the 3rd International Meeting on Respiratory Pathogens in Singapore (17–20 September 2025), examined evolving approaches to prevention and management of respiratory infections.
Narmadha Morvil, Wilson Guo Wei Goh, Charlotte Zheng, Stephanie Sutjipto, Dorothy Hui Lin Ng, Maria Zambon   +5 more
wiley   +1 more source

Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors. [PDF]

Adv Sci (Weinh)
Duffy JT, Martin-Regalado A, Haupt BE, Pogue JR, Thakur A, Cota MF, Zannikou M, Misener S, Krymskaya VP, McCortney K, Miska J, Horbinski C, Simberg D, Lesniak MS, James CD, Stupp R, Balyasnikova IV.   +16 more
europepmc   +1 more source

Erratum: A KRAS^G12V-targeted bispecific T cell engager promotes immunity against colorectal solid tumor. [PDF]

Mol Ther Oncol
Huynh N, Thi Nguyen TM, Bui NT, Nguyen HN, Nguyen CT.   +4 more
europepmc   +1 more source

Characterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative. [PDF]

Int J Mol Sci
Saha N, Lee SG, de Stanchina E, Mendoza RP, Veach DR, Nikolov DB.   +5 more
europepmc   +1 more source

A novel CLDN6 nanobody-based bispecific T-cell engager delivered by self-amplifying RNA platform exhibits potent antitumor efficacy. [PDF]

J Nanobiotechnology
Zhu Z, Li J, Lu Q, Zeng W, Yu Z, Liu N, Zhang Z, Wang Z, Yang N, Chen Y, Lu H, Xu L, Nie C, Li H, Tong A.   +14 more
europepmc   +1 more source

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer. [PDF]

Mol Ther Oncolytics, 2023
Liu S, Li F, Deng L, Ma Q, Lu W, Zhao Z, Liu H, Zhou Y, Hu M, Wang H, Yan Y, Zhao M, Zhang H, Du M.   +13 more
europepmc   +1 more source